Measurement of cytokines, bloodflow and erythema after shear- force application of the skin in patients with Diabetes Mellitus

Measurement of cytokines, bloodflow and erythema after shear- force application of the skin in patients with Diabetes Mellitus - The effect of shear- force in patients with Diabetes Mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42149

Enrollment

Registered

2015-02-11

Start date

2015-04-15

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pressure sores Pressure ulcer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Group A: - Healthy volunteers - age 40 years or older and 75 years and younger;Group B; - patients with Diabetes Mellitus type 2 (DM) without neuropathy - age 40 years or older and 75 years and younger - Valk score 4;Group D - Patients with (pre)- existing Charcot Ostheoarhtropathy - age 40 years or older and 75 years and younger - Valk score > 4;In all patients we are going to determine the Valk score to measure the amount of neuropathy in patients. The Valk score is going to be determined by someone of the research committee, or under the supervision of someone of the research committee.

Exclusion criteria

Exclusion criteria: - Trauma fore arms - Skin diseases (psoriasis, eczema) - NSAID use in last seven days - Corticosteroïds - Auto- iimune diseases - Muscular dystrophy - Malignancy - Participant is unable to give informed consent - No peripheral pulsations (a. radialis, a. dorsalis pedis, a. tibialis anterior) - Hab1c percentage last 3 months > 11%

Design outcomes

Primary

Measure	Time frame
1. IL-1 */ totale protein ratio 2. Bloodflow of the skin (in flux ) 3. Erythema index of the skin 4. Cutaneous microbiome	—

Countries

Netherlands

Outcome results